Incyte Stock News

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of December: Citi's 2025 Global Healthcare Conference on Tuesday, December 2, 2025 at 11:15 am (EST) 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 1:20 pm (EST) The presentations will be webcast live and can be accessed...

Incyte Corporation ( INCY ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:00 AM EST Company Participants William Meury - CEO, President & Director Pablo Cagnoni - President and Head of Research & Development Conference Call Participants Yuxi Dong - Jefferies LLC, Research Division Presentation Yuxi Dong Jefferies LLC, Research Division All right. Good morning.

The healthcare sector's renewed momentum offers fertile ground for investors wanting to outperform by picking the best stocks from the broader indexes. Goldman Sachs identified 29 healthcare stocks in the Russell 1000 universe with positive recent consensus revisions to 2026 EPS estimates and that trade at attractive valuations. Goldman sees "more opportunity for alpha than beta" as wide return...

MORGES, Switzerland--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL).

Incyte Corporation ( INCY ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10, 2025 10:00 AM EST Company Participants William Meury - CEO, President & Director Pablo Cagnoni - President and Head of Research & Development Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Presentation Michael Schmidt Guggenheim Securities, LLC...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte's Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema.

No single month beats November for S&P 500 stock market performance. And a handful of stocks are already taking off.

Biotech stocks have rebounded after years of underperformance but remain well below their 2021 highs. Successful drug launches, strong trial results, and falling interest rates have boosted stock prices, while M&A activity pushes valuations higher. The biotech rally could be sustainable, analysts say, with biotech firms more disciplined and increasingly profitable, while startups avoid launchin...